An object of the invention is to provide a means for accomplishing inactivation of a pathogen in a blood sample containing red blood cells and platelets together, as well as sufficiently reducing the hemolysis rate of the red blood cell product finally obtained.

The means is to irradiate ultraviolet ray to a blood sample containing red blood cells and platelets in the presence of a hemolysis inhibitor and a surfactant having an HLB value of 13 or greater and having the number of oxyethylene groups of a hydrophilic portion in the molecular structure of 20 or greater when producing a blood product containing red blood cells and platelets.

An object of the invention is to provide a means for accomplishing inactivation of a pathogen in a blood sample containing red blood cells and platelets together, as well as sufficiently reducing the hemolysis rate of the red blood cell product finally obtained.

The means is to irradiate ultraviolet ray to a blood sample containing red blood cells and platelets in the presence of a hemolysis inhibitor and a surfactant having an HLB value of 13 or greater and having the number of oxyethylene groups of a hydrophilic portion in the molecular structure of 20 or greater when producing a blood product containing red blood cells and platelets.

The present invention relates to a blood bag system, a method for its manufacture, and a process for reducing pathogens and leucocytes in biological fluids in particular in therapeutic quantities of platelet concentrates (PC) contained in the blood bag system, using UV-light and agitation, wherein part of the plasma of the PC is optionally exchanged against a platelet additive solution.

Provided herein are compositions, systems, kits, and methods for treating cancer in a subject with androgen receptor positive cancer cells by sensitizing such cancer cells with anti-androgen receptor therapy (e.g., Enzalutamide or anti-androgen antibody), and then treating with radiation therapy.

A responsive hydrogel-based material may be used as a carrier system for the in situ delivery of various cargo substances, including bioactive moieties. The hydrogel structure, which includes photodegradable and thioether moieties in its three dimensional network, enables finely tuned local release of cargo substances as a function of the in vivo tissue environment (e.g., enzyme concentration or reducing environment) and externally applied stimuli (e.g., light) by selective spatiotemporal hydrogel degradation.

The present invention relates to an injectable pharmaceutical composition containing a prodrug of caspase inhibitors, and a preparation method therefor. More specifically, the present invention relates to an injectable pharmaceutical composition, and a preparation method therefor, the composition comprising, as an active ingredient, (2S,3S)-2-(fluoromethyl)-3-((R)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydroisoxazole-5-carboxamido)-5-oxotetrahydrofuran-2-yl acetate, which is a prodrug of caspase inhibitors, or a pharmaceutically acceptable salt or isomer thereof, and comprising, as a biocompatible polymer, microspheres containing poly(lactide-co-glycolide).

The present invention relates to an injectable pharmaceutical composition containing a prodrug of caspase inhibitors, and a preparation method therefor. More specifically, the present invention relates to an injectable pharmaceutical composition, and a preparation method therefor, the composition comprising, as an active ingredient, (2S,3S)-2-(fluoromethyl)-3-((R)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydroisoxazole-5-carboxamido)-5-oxotetrahydrofuran-2-yl acetate, which is a prodrug of caspase inhibitors, or a pharmaceutically acceptable salt or isomer thereof, and comprising, as a biocompatible polymer, microspheres containing poly(lactide-co-glycolide).

A method of treating pulmonary metastasis of osteosarcoma cells (pOSs) in a subject in need thereof includes administering to the subject a therapeutically effective amount of an agent that interferes with VCAM-1/α4β1 signaling between pOSs expressing VCAM-1 and pulmonary macrophages (MACs) expressing α4β1.

A method of treating pulmonary metastasis of osteosarcoma cells (pOSs) in a subject in need thereof includes administering to the subject a therapeutically effective amount of an agent that interferes with VCAM-1/α4β1 signaling between pOSs expressing VCAM-1 and pulmonary macrophages (MACs) expressing α4β1.

The present invention relates to a method of preparing a live attenuated vaccine by irradiation and a live attenuated vaccine composition prepared by the same, and more particularly, a method of preparing a live attenuated vaccine by irradiation including irradiating a pathogenic microorganism with a dose of 0.5 to 2 kGy of radiation per single radiation six to fifteen times; and a live attenuated vaccine composition including a pathogenic microorganism attenuated to not be revertant to a wild type by generation of at least one mutation of nucleotide insertion and nucleotide deletion by irradiation.